Boiardi A, Silvani A, Milanesi I, Munari L, Broggi G, Botturi M
Istituto Nazionale Neurologico C. Besta, Milano.
Ital J Neurol Sci. 1991 Apr;12(2):163-8. doi: 10.1007/BF02337028.
Dosage and schedules for the treatment of malignant glial tumors using IFN (interferon) are still uncertain and controversial. In this study we give the preliminary results of treatment in 28 patients with glioblastoma multiforme (GBM). 6 patients were treated with local injection of beta-IFN through an Ommaya reservoir; 4 patients with beta-IFN followed by systemic chemotherapy (Cisplatin + Etoposide), and 18 patients with chemotherapy only. Two end points were evaluated: 1) Whether or not the patients responded to treatment. 2) Length of Time to Tumor Progression (TTP) after surgery. We found that IFN alone was ineffective. Results were improved when local immunotherapy was associated with systemic chemotherapy. New drugs and investigation of possible pharmacological synergism are needed.
使用干扰素（IFN）治疗恶性胶质细胞瘤的剂量和疗程仍不确定且存在争议。在本研究中，我们给出了28例多形性胶质母细胞瘤（GBM）患者的初步治疗结果。6例患者通过Ommaya储液器进行β-IFN局部注射治疗；4例患者先接受β-IFN治疗，随后进行全身化疗（顺铂+依托泊苷），18例患者仅接受化疗。评估了两个终点：1）患者是否对治疗有反应。2）手术后肿瘤进展时间（TTP）的长短。我们发现单独使用IFN无效。当局部免疫治疗与全身化疗联合使用时，结果有所改善。需要新药并研究可能的药理协同作用。
